Sex differences in monitoring and achievement of blood pressure and LDL-cholesterol targets in chronic coronary syndrome

  • Elin Täufer Cederlöf Department of Medical Sciences, Cardiology and Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden https://orcid.org/0000-0001-7523-0511
  • Jessica Schubert Department of Medical Sciences, Cardiology and Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden https://orcid.org/0000-0002-1917-5885
  • Nina Johnston Department of Medical Sciences, Cardiology and Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden
  • Maria K. Svensson Renal Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden; and Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden https://orcid.org/0000-0001-7545-5585
  • Thomas Cars Sence Research AB, Uppsala, Sweden
  • Lovisa Schalin Amgen AB, Solna, Sweden https://orcid.org/0009-0000-3541-6514
  • Emil Hagström Department of Medical Sciences, Cardiology and Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden; and Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden https://orcid.org/0000-0003-3221-0144
Keywords: Coronary Artery Disease, Secondary Prevention, LDL Cholesterol, Blood Pressure, Sex Differences

Abstract

Background: The cornerstones of secondary prevention in chronic coronary syndrome (CCS) are blood pressure lowering and lipid-lowering therapy (LLT). The purpose of this study was to examine the control of systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) in patients with CCS followed in primary care.

Methods: This was a retrospective population-based cohort study of patients diagnosed with CCS at cardiology clinics in Uppsala Region, Sweden, between 2012 and 2020. Data from electronic health records were analyzed for SBP and LDL-C monitoring and secondary prevention target achievement during 3 years of follow-up, stratified by sex, age, and diabetes status. Sex differences in time to LLT initiation during the first year after CCS diagnosis were evaluated using Cox proportional hazards models.

Results: In total, 1,452 patients (415 women and 1,037 men) were followed for a median of 3.2 years (interquartile range [IQR]: 1.4–5.8). Most patients had at least one SBP measurement during follow-up, and approximately half met SBP targets (50.9% of women and 56.1% of men at year 1). LDL-C monitoring was less common: at year 1, 40.8% of women and 28.7% of men lacked a measurement, and targets were achieved in 12.1% of women and 24.7% of men. By year 3, target achievement had declined further to 11.2 and 15.0%, respectively. Women were less likely than men to initiate LLT within the first year (adjusted hazard ratio 0.70, 95% confidence interval: 0.61–0.80, P < 0.001). LLT use also declined over time, with 54.1% of women versus 73.9% of men on treatment at year 3 (P < 0.001).

Conclusion: Large gaps in secondary prevention of patients with CCS were observed, with under-monitoring of LDL-C and declining use of LLT, particularly among women. Although SBP was routinely assessed, only half of patients achieved recommended levels. These findings highlight the need for systematic strategies in primary care to improve management in CCS.

Downloads

Download data is not yet available.

References


1.
Ogmundsdottir Michelsen H, Sjolin I, Schlyter M, Hagstrom E, Kiessling A, Henriksson P, et al. Cardiac rehabilitation after acute myocardial infarction in Sweden – evaluation of programme characteristics and adherence to European guidelines: the Perfect Cardiac Rehabilitation (Perfect-CR) study. Eur J Prev Cardiol. 2020;27:18–27. doi: 10.1177/2047487319865729

2.
Back M, Leosdottir M, Hagstrom E, Norhammar A, Hag E, Jernberg T, et al. The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). Eur Heart J Qual Care Clin Outcomes. 2021;7:431–7. doi: 10.1093/ehjqcco/qcab039

3.
Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824–35. doi: 10.1177/2047487318825350

4.
De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Ryden L, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46. doi: 10.1016/j.atherosclerosis.2019.03.014

5.
Vasko P. SWEDEHEART Annual report 2023. 2024. Available from: https://www.ucr.uu.se/swedeheart/dokument-sh/arsrapporter-sh/arsrapporter-sh- [cited 1 August 2026].

6.
Allahyari A, Jernberg T, Lautsch D, Lundman P, Hagstrom E, Schubert J, et al. Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013–17. Eur Heart J Qual Care Clin Outcomes. 2021;7:59–67. doi: 10.1093/ehjqcco/qcaa016

7.
Odesjo H, Bjorck S, Franzen S, Hjerpe P, Manhem K, Rosengren A, et al. Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study. BMJ Open. 2020;10:e036920. doi: 10.1136/bmjopen-2020-036920

8.
Mesnier J, Giovachini L, Ducrocq G, Ferrari R, Ford I, Tendera M, et al. Sex differences in management of LDL-cholesterol in patients with chronic coronary syndrome. Eur Heart J. 2024;45(Supplement_1). doi: 10.1093/eurheartj/ehae666.1326

9.
Schamroth Pravda N, Karny-Rahkovich O, Shiyovich A, Schamroth Pravda M, Rapeport N, Vaknin-Assa H, et al. Coronary Artery disease in women: a comprehensive appraisal. J Clin Med. 2021;10(20):4664. doi: 10.3390/jcm10204664

10.
Peters SAE, Colantonio LD, Chen L, Bittner V, Farkouh ME, Rosenson RS, et al. Sex differences in incident and recurrent coronary events and all-cause mortality. J Am Coll Cardiol. 2020;76:1751–60. doi: 10.1016/j.jacc.2020.08.027

11.
Rao U, Buchanan GL, Hoye A. Outcomes after percutaneous coronary intervention in women: are there differences when compared with men? Interv Cardiol. 2019;14:70–5. doi: 10.15420/icr.2019.09

12.
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415–537. doi: 10.1093/eurheartj/ehae177

13.
Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B, Steering Committee of the Swedish National Diabetes R. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003;26:1270–6. doi: 10.2337/diacare.26.4.1270

14.
Eliasson B, Gudbjornsdottir S. Diabetes care – improvement through measurement. Diabetes Res Clin Pract. 2014;106 Suppl 2:S291–4. doi: 10.1016/S0168-8227(14)70732-6

15.
Bjork J, Grubb A, Sterner G, Nyman U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmo Study cohort. Scand J Clin Lab Invest. 2011;71:232–9. doi: 10.3109/00365513.2011.557086

16.
Ludvigsson JF, Appelros P, Askling J, Byberg L, Carrero JJ, Ekstrom AM, et al. Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin Epidemiol. 2021;13:21–41. doi: 10.2147/CLEP.S282475

17.
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268–74. doi: 10.7326/M16-2607

18.
Warren JR, Falster MO, Tran B, Jorm L. Association of continuity of primary care and statin adherence. PLoS One. 2015;10:e0140008. doi: 10.1371/journal.pone.0140008

19.
Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open Heart. 2020;7(2). doi: 10.1136/openhrt-2020-001396

20.
Karlsson SA, Franzen S, Svensson AM, Miftaraj M, Eliasson B, Andersson Sundell K. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. BMC Health Serv Res. 2018;18:900. doi: 10.1186/s12913-018-3707-4

21.
Bentzel S, Ljungman C, Hjerpe P, Schioler L, Manhem K, Bengtsson Bostrom K, et al. Long-term secondary prevention and outcome following acute coronary syndrome: real-world results from the Swedish Primary Care Cardiovascular Database. Eur J Prev Cardiol. 2024;31:812–21. doi: 10.1093/eurjpc/zwad389

22.
Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279–89. doi: 10.1093/eurjpc/zwaa047

23.
Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. doi: 10.1016/j.lanepe.2023.100624

24.
Kotseva K, Investigators E. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovasc Diagn Ther. 2017;7:633–9. doi: 10.21037/cdt.2017.04.06

25.
Groenhof TKJ, Asselbergs FW, Groenwold RHH, Grobbee DE, Visseren FLJ, Bots ML, et al. The effect of computerized decision support systems on cardiovascular risk factors: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2019;19:108. doi: 10.1186/s12911-019-0824-x

26.
Ruiz-Ortiz M, Sanchez-Fernandez C, Sanchez-Fernandez JJ, Mateos-de-la-Haba L, Barreiro-Mesa L, Ogayar-Luque C, et al. Long-term prognostic impact of sex in patients with chronic coronary syndrome: a 17-year prospective cohort study. J Womens Health (Larchmt). 2023;32:63–70.

27.
Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2020;41:347–56. doi: 10.1093/eurheartj/ehz660

28.
Witting C, Devareddy A, Rodriguez F. Review of lipid-lowering therapy in women from reproductive to postmenopausal years. Rev Cardiovasc Med. 2022;23(5).

29.
Bytyci I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213–23. doi: 10.1093/eurheartj/ehac015

30.
Swedish Association of General Practice. Kloka Kliniska Val inom allmänmedicin. 2025. Available from: https://forening.sls.se/media/1fglj3jx/kloka-kliniska-val-inom-allmanmedicin-250312-1.pdf [cited 10 Feburary 2026].

31.
Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2023;38:147–55. doi: 10.1007/s11606-022-07707-x

32.
Privett N, Guerrier S. Estimation of the time needed to deliver the 2020 USPSTF preventive care recommendations in primary care. Am J Public Health. 2021;111:145–9. doi: 10.2105/AJPH.2020.305967

33.
McCormack JP, Holmes DT. Your results may vary: the imprecision of medical measurements. BMJ. 2020;368:m149. doi: 10.1136/bmj.m149

34.
Stenehjem K, Herren D, Pulver G, Combs B. Association of frequency of lipid testing with changes in lipid-lowering therapy. JAMA Intern Med. 2017;177:1529–31. doi: 10.1001/jamainternmed.2017.3954

35.
Kolber MR, Klarenbach S, Cauchon M, Cotterill M, Regier L, Marceau RD, et al. PEER simplified lipid guideline 2023 update: prevention and management of cardiovascular disease in primary care. Can Fam Physician. 2023;69:675–86. doi: 10.46747/cfp.6910675
Published
2026-08-31
How to Cite
Täufer Cederlöf , E., Schubert , J., Johnston , N., Svensson , M. K., Cars , T., Schalin , L., & Hagström , E. (2026). Sex differences in monitoring and achievement of blood pressure and LDL-cholesterol targets in chronic coronary syndrome. Upsala Journal of Medical Sciences, 131, e14047. https://doi.org/10.48101/ujms.v131.14047